BR112020011310A2 - anticorpos contra fcrn e seus métodos de uso - Google Patents
anticorpos contra fcrn e seus métodos de uso Download PDFInfo
- Publication number
- BR112020011310A2 BR112020011310A2 BR112020011310-7A BR112020011310A BR112020011310A2 BR 112020011310 A2 BR112020011310 A2 BR 112020011310A2 BR 112020011310 A BR112020011310 A BR 112020011310A BR 112020011310 A2 BR112020011310 A2 BR 112020011310A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- sequence
- antibody
- fcrn
- cdr
- Prior art date
Links
- 0 C(CCC1(C2)C=CC2C1)C[C@]1*=C1 Chemical compound C(CCC1(C2)C=CC2C1)C[C@]1*=C1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US62/598,402 | 2017-12-13 | ||
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| US62/701,354 | 2018-07-20 | ||
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020011310A2 true BR112020011310A2 (pt) | 2020-11-17 |
Family
ID=65041911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020011310-7A BR112020011310A2 (pt) | 2017-12-13 | 2018-12-13 | anticorpos contra fcrn e seus métodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11773168B2 (https=) |
| EP (1) | EP3723802A1 (https=) |
| JP (3) | JP7420720B2 (https=) |
| KR (2) | KR102904658B1 (https=) |
| CN (1) | CN111712259A (https=) |
| AU (1) | AU2018386193B2 (https=) |
| BR (1) | BR112020011310A2 (https=) |
| CA (1) | CA3085751A1 (https=) |
| IL (1) | IL275070A (https=) |
| NZ (1) | NZ765250A (https=) |
| SG (1) | SG11202005021PA (https=) |
| WO (1) | WO2019118791A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| JP2023509195A (ja) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | 天疱瘡症を治療する方法 |
| AU2021292200A1 (en) * | 2020-06-17 | 2023-02-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| US20240182598A1 (en) * | 2021-04-12 | 2024-06-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating pediatric myasthenia gravis |
| CN116234827A (zh) * | 2021-09-03 | 2023-06-06 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| KR20240134900A (ko) * | 2022-01-17 | 2024-09-10 | 아르젠엑스 비브이 | 자가항체 매개 질환 환자를 치료하기 위한 방법 |
| CN119698429A (zh) | 2022-06-15 | 2025-03-25 | 阿根思有限公司 | Fcrn结合分子及使用方法 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| CN121909214A (zh) | 2023-07-31 | 2026-04-21 | 玫帝托克斯股份有限公司 | 一种抗体及包含该抗体的用于治疗免疫疾病的药物组合物 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| ES2569409T3 (es) | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| US20110059101A9 (en) | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
| WO2009131702A2 (en) | 2008-04-25 | 2009-10-29 | Dyax Corp. | Antibodies against fcrn and use thereof |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| ES2765874T3 (es) * | 2011-05-25 | 2020-06-11 | Innate Pharma Sa | Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios |
| AU2012262007B2 (en) | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| ES2802274T3 (es) | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| PL3137504T3 (pl) | 2014-04-30 | 2023-10-16 | Hanall Biopharma Co., Ltd. | Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych |
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| EP3294335B1 (en) * | 2015-05-12 | 2023-07-05 | Syntimmune Inc. | Humanized affinity matured anti-fcrn antibodies |
| SMT202400004T1 (it) | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| WO2019160979A1 (en) | 2018-02-13 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Therapeutic fcrn-based bispecific monoclonal antibodies |
| WO2020023310A1 (en) | 2018-07-20 | 2020-01-30 | Williams Eva | Compositions of fcrn antibodies and methods of use thereof |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| CN113646051A (zh) | 2018-10-16 | 2021-11-12 | Ucb生物制药有限责任公司 | 重症肌无力的治疗方法 |
| EP4007605A4 (en) | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
| IL302516A (en) | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
-
2018
- 2018-12-13 KR KR1020207019955A patent/KR102904658B1/ko active Active
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 KR KR1020257042733A patent/KR20260008175A/ko active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 NZ NZ765250A patent/NZ765250A/en unknown
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en active Pending
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP2025143252A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102904658B1 (ko) | 2025-12-29 |
| AU2018386193A8 (en) | 2020-07-02 |
| CA3085751A1 (en) | 2019-06-20 |
| JP2021506786A (ja) | 2021-02-22 |
| CN111712259A (zh) | 2020-09-25 |
| JP2024016042A (ja) | 2024-02-06 |
| US11773168B2 (en) | 2023-10-03 |
| SG11202005021PA (en) | 2020-07-29 |
| JP2025143252A (ja) | 2025-10-01 |
| US20220064290A1 (en) | 2022-03-03 |
| AU2018386193B2 (en) | 2025-04-24 |
| JP7420720B2 (ja) | 2024-01-23 |
| US20240158509A1 (en) | 2024-05-16 |
| KR20200098604A (ko) | 2020-08-20 |
| WO2019118791A1 (en) | 2019-06-20 |
| EP3723802A1 (en) | 2020-10-21 |
| AU2018386193A1 (en) | 2020-06-25 |
| JP7690538B2 (ja) | 2025-06-10 |
| KR20260008175A (ko) | 2026-01-15 |
| IL275070A (en) | 2020-07-30 |
| NZ765250A (en) | 2026-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7690538B2 (ja) | ＦｃＲｎ抗体およびその使用方法 | |
| JP7442575B2 (ja) | Ｆｃｒｎ抗体及びその使用方法 | |
| BR122025025099A2 (pt) | Anticorpos contra fcrn, usos dos mesmos e composições | |
| HK40104376A (en) | Fcrn antibodies and methods of use thereof | |
| HK40002836A (en) | Fcrn antibodies and methods of use thereof | |
| HK40002836B (en) | Fcrn antibodies and methods of use thereof | |
| BR122024008593A2 (pt) | Anticorpo isolado que se liga ao fcrn humano, seus usos e seu método de preparação, bem como molécula de ácido nucleico, vetor, célula hospedeira e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025025099-6 PROTOCOLO 870250104728 EM 14/11/2025 19:21. |